Literature DB >> 8610467

Myristylation of the large surface protein is required for hepatitis B virus in vitro infectivity.

V Bruss1, J Hagelstein, E Gerhardt, P R Galle.   

Abstract

The large surface protein (L) of the enveloped hepatitis B virus (HBV) is myristylated at glycine 2. To investigate whether this fatty acid moiety is required for HBV infectivity we made use of a point mutant in which the myristyl acceptor was mutated to a nonfunctional alanine. The mutant virus and a wild-type control were expressed in a human hepatoma cell line by transfection of genomic DNA constructs. Comparable amounts of virions were secreted by both strains as measured by the endogenous polymerase activity of immunoprecipitated virions. The presentation of an N-terminal epitope of L on the virion surface was not influenced by the mutation. To test the infectivity of this mutant virus primary human hepatocytes were incubated with the media of transfected cells. The covalently circular closed HBV DNA molecules generated after infection were discriminated from the open circular DNA genomes of inoculated virions by a sensitive PCR-based technique. The experiments demonstrated that the wild type was infectious but not the myristate negative mutant. This reflects the phenotype of an homologous duck hepatitis B virus mutant although the N-terminal L protein domains of this virus and of HBV show no primary sequence homology.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8610467     DOI: 10.1006/viro.1996.0209

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  44 in total

1.  Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion.

Authors:  Jennifer A Corcoran; Roy Duncan
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 3.  Viral and cellular determinants involved in hepadnaviral entry.

Authors:  Dieter Glebe; Stephan Urban
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

4.  Two potentially important elements of the hepatitis B virus large envelope protein are dispensable for the infectivity of hepatitis delta virus.

Authors:  Severin Gudima; Anja Meier; Roland Dunbrack; John Taylor; Volker Bruss
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 5.  Host functions used by hepatitis B virus to complete its life cycle: Implications for developing host-targeting agents to treat chronic hepatitis B.

Authors:  Bidisha Mitra; Roshan J Thapa; Haitao Guo; Timothy M Block
Journal:  Antiviral Res       Date:  2018-08-24       Impact factor: 5.970

6.  Fine mapping of pre-S sequence requirements for hepatitis B virus large envelope protein-mediated receptor interaction.

Authors:  Andreas Schulze; Alexa Schieck; Yi Ni; Walter Mier; Stephan Urban
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

7.  Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity.

Authors:  J Le Seyec; P Chouteau; I Cannie; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Infection process of the hepatitis B virus depends on the presence of a defined sequence in the pre-S1 domain.

Authors:  J Le Seyec; P Chouteau; I Cannie; C Guguen-Guillouzo; P Gripon
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

9.  Analysis of host range phenotypes of primate hepadnaviruses by in vitro infections of hepatitis D virus pseudotypes.

Authors:  Azeneth Barrera; Bernadette Guerra; Helen Lee; Robert E Lanford
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  The translocation motif of hepatitis B virus envelope proteins is dispensable for infectivity.

Authors:  Charlotte Lepère; Morgane Régeard; Jacques Le Seyec; Philippe Gripon
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.